Covid-19 Vaccine

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Total publications:37 publications

Grant number: COV19OxfordVaccine01

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2024
  • Known Financial Commitments (USD)

    $41,574,205.62
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
  • Principal Investigator

    N/A

  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Oxford
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Covid-19 Vaccine

Publicationslinked via Europe PMC

Last Updated:37 minutes ago

View all publications at Europe PMC

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.